David M. Swoboda

David M. Swoboda

Auto-generated profile, based on publicly available information

David M. Swoboda

University of South Florida Morsani College of Medicine, Tampa, FL, United States; Tampa General Hospital Cancer Institute, Tampa, FL, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
AMAbhishek A. Mangaonkar
Abhishek A. Mangaonkar
DSDavid M. Swoboda
David M. Swoboda
GCGiacomo Coltro
Giacomo Coltro
TLTerra L. Lasho
Terra L. Lasho
PNPaul J. Novotny
Paul J. Novotny
MPMrinal M. Patnaik
Mrinal M. Patnaik

27 January 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
DRDaniel R. Richardson
Daniel R. Richardson
DSDavid M. Swoboda
David M. Swoboda
DMDominic T. Moore
Dominic T. Moore
SJSteven M. Johnson
Steven M. Johnson
OCOnyee Chan
Onyee Chan
JZJoshua F. Zeidner
Joshua F. Zeidner

1 October 2021 in Leukemia Research
Verified
Journal Article
Closed access
Anthony Michael HunterAnthony Michael Hunter
Anthony Michael Hunter
NANajla Al Ali
Najla Al Ali
AMAnne Mai
Anne Mai
SSSavan Shah
Savan Shah
DSDavid M. Swoboda
David M. Swoboda
EPEric Padron
Eric Padron

1 November 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
DSDavid M. Swoboda
David M. Swoboda
NANajla Al Ali
Najla Al Ali
OCOnyee Chan
Onyee Chan
EPEric Padron
Eric Padron
AKAndrew T. Kuykendall
Andrew T. Kuykendall
RKRami S. Komrokji
Rami S. Komrokji

3 January 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
DSDavid M. Swoboda
David M. Swoboda
Rashmi Kanagal-ShamannaRashmi Kanagal-Shamanna
Rashmi Kanagal-Shamanna
ABAndrew M. Brunner
Andrew M. Brunner
TCThomas Cluzeau
Thomas Cluzeau
OCOnyee Chan
Onyee Chan
DSDavid Sallman
David Sallman

23 July 2021 in Blood
Verified
Journal Article
Closed access
PDF file
RKRami S. Komrokji
Rami S. Komrokji
VVVirginia Olivia Volpe
Virginia Olivia Volpe
OCOnyee Chan
Onyee Chan
NANajla H Al Ali
Najla H Al Ali
DSDavid M. Swoboda
David M. Swoboda
DSDavid A. Sallman
David A. Sallman
Komrokji et al examined the proposed international working group proposal to designate SF3B1-mutant myelodysplastic syndrome (MDS) as a unique disease entity, using a single-institution validation cohort of 1779 MDS patients, of whom 320 harbored SF3B1 mutations. They confirmed the demographics of older age, low-risk disease, ring sideroblasts, and low blast percentage. They further confirmed better overall survival that is negatively impacted in those patients with concomitant mutations, high variant allele fraction, and increased blast percentage.